Contrasting Golub Capital BDC (NASDAQ:GBDC) & Biosig Technologies (NASDAQ:STEX)

Golub Capital BDC (NASDAQ:GBDC) and Biosig Technologies (NASDAQ:STEX) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Golub Capital BDC and Biosig Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Golub Capital BDC	0	2	4	1	2.86
Biosig Technologies	1	0	1	0	2.00

Golub Capital BDC presently has a consensus target price of $13.90, suggesting a potential upside of 8.76%. Biosig Technologies has a consensus target price of $4.00, suggesting a potential upside of 466.57%. Given Biosig Technologies’ higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Golub Capital BDC.

Volatility & Risk

Golub Capital BDC has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Valuation and Earnings

This table compares Golub Capital BDC and Biosig Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Golub Capital BDC	$870.78 million	3.81	$376.65 million	$0.65	19.66
Biosig Technologies	$40,000.00	2,055.52	-$462.77 million	($9.05)	-0.08

Golub Capital BDC has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Golub Capital BDC, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Golub Capital BDC and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Golub Capital BDC	21.45%	9.91%	4.39%
Biosig Technologies	N/A	-462.48%	-307.38%

Institutional & Insider Ownership

42.4% of Golub Capital BDC shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 1.4% of Golub Capital BDC shares are held by insiders. Comparatively, 52.7% of Biosig Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Golub Capital BDC beats Biosig Technologies on 11 of the 15 factors compared between the two stocks.

About Golub Capital BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.